T Zellweger
Overview
Explore the profile of T Zellweger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wetterauer C, Weibel M, Gsponer J, Vlajnic T, Zellweger T, Butikofer S, et al.
Virchows Arch
. 2014 Oct;
465(6):629-36.
PMID: 25269630
The reported incidental prostate cancer prevalence rates at radical cystoprostatectomy cover a range from 4 to 60 %. We investigated the influence of the histopathological work-up on prostate cancer prevalence...
2.
Gsponer J, Braun M, Scheble V, Zellweger T, Bachmann A, Perner S, et al.
Prostate Cancer Prostatic Dis
. 2014 Jan;
17(2):126-31.
PMID: 24469092
Background: Approximately half of the prostate carcinomas are characterized by a chromosomal rearrangement fusing the androgen-regulated gene TMPRSS2 to the oncogenic ETS transcription factor ERG. Aim of this study was...
3.
Vedana M, Geisler S, Zellweger T, Gasser T
Rev Med Suisse
. 2013 Dec;
9(407):2184-8.
PMID: 24354254
In Switzerland, renal cancer represents 2% of adult neoplasia and its incidence is 8,2 cases per 100000 people. Small renal masses (< 4 cm) are mostly found incidentally during ultrasound...
4.
Zellweger T, Benz G, Herzog M, Grilli B, Mihatsch M, Gasser T, et al.
Verh Dtsch Ges Pathol
. 2006 Aug;
88:194-8.
PMID: 16892552
The early detection of recurrent urothelial cancer is a great challenge for both urologists and pathologists. Cytology is a sensitive and highly specific tool for the diagnosis of high-grade bladder...
5.
Zellweger T, Gasser T
Praxis (Bern 1994)
. 2005 Sep;
94(34):1307-8.
PMID: 16170999
No abstract available.
6.
Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, et al.
BJU Int
. 2003 Aug;
92(4):463-9.
PMID: 12930442
Objective: To evaluate the effect of clusterin overexpression on radiation-induced tumour growth rates and apoptosis in human prostate LNCaP cells, as prostate cancer cells are relatively resistant to radiation-induced apoptosis...
7.
Miyake H, Hara S, Zellweger T, Kamidono S, Gleave M, Hara I
Mol Urol
. 2001 Nov;
5(3):105-11.
PMID: 11690557
Recent studies have shown the antiapoptotic activity of clusterin against a wide variety of stimuli; however, the functional role of clusterin in Fas-mediated apoptosis has not been well characterized. We...
8.
Zellweger T, Miyake H, July L, Akbari M, Kiyama S, Gleave M
Neoplasia
. 2001 Sep;
3(4):360-7.
PMID: 11571636
Background: Renal cell cancer (RCC) is a chemoresistant disease with no active chemotherapeutic agent achieving objective response rates higher than 15%. Clusterin is a cell survival gene that increases in...
9.
Zellweger T, Miyake H, Cooper S, Chi K, Conklin B, Monia B, et al.
J Pharmacol Exp Ther
. 2001 Aug;
298(3):934-40.
PMID: 11504787
Phosphorothioate (P=S) antisense oligonucleotides (ASO) targeting the cell survival gene clusterin synergistically enhance castration- and chemotherapy-induced apoptosis in prostate cancer xenografts. This study compares efficacy, tissue half-lives, and toxicity of...
10.
Gleave M, Miyake H, Zellweger T, Chi K, July L, Nelson C, et al.
Urology
. 2001 Aug;
58(2 Suppl 1):39-49.
PMID: 11502446
Background: Androgen resistance develops, in part, from upregulation of antiapoptotic genes after androgen withdrawal. Identification and targeting of genes mediating androgen-independent (AI) progression may lead to development of novel therapies...